Researchers and companies are devising promising approaches to circumvent limitations of existing transfection technologies. Ongoing challenges, particularly with regard to high-quality recombinant ...
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein ...
In recent years, AAV manufacturing processes have evolved significantly to not only address the need for later-stage clinical and commercial supplies, but also to address regulatory concerns around ...
In this interview, News Med talks to Hinnah Campwala about the pivotal role of transfection in modern research and drug discovery. Transfection is a tool that sees widespread use across a diverse ...
Cell and gene therapies are changing lives. They engineer patients’ cells or DNA to create personalized therapies, unlocking long-lasting or even curative treatments for diseases with high unmet needs ...
WEST BOYLSTON, Mass. & SOUTHBRIDGE, Mass.--(BUSINESS WIRE)--TransCytos: NEVER BEEN DONE BEFORE Enginasion and TransCytos announced today that their collaboration has resulted in a prototype ...
insights from industryJames BradySenior Vice PresidentMaxCyte, Inc. In this interview, NewsMedical talks to James Brady about cell-based therapy and how the field of genetic engineering transformed.
a) A laser scanning microscope image of a cancer cell used in the experiment is shown. The green circles show plasmid-coated particles that have been optically tweezed and inserted into the cell. b) ...
AAV-mediated gene therapy is a quickly growing segment of the pharmaceutical market; however, the current transient transfection process to produce rAAV has several challenges. The stable cells are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback